

*1634*  
*KFW*

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the US Postal Service with sufficient postage as First Class Mail in an envelope addressed to Mail Stop Missing Parts, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Date: May 24, 2005

By: Mari Kleineidam  
Mari Kleineidam



**PATENT**  
Attorney Docket No. GC634-2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of	)	Group Art Unit: 1636
BRON et al.	)	Examiner: LEFFERS, Jr., Gerald G.
Serial No.: 09/954,737	)	
Filed: September 17, 2001	)	
For: TWIN-ARGININE	)	
TRANSLOCATION IN BACILLUS	)	

RESPONSE TO THE OFFICE COMMUNICATION/NOTICE TO COMPLY

Mail Stop Missing Parts  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In complete response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures dated May 2, 2005, enclosed please find:

- Four sets of the Combined Declaration and Power of Attorney signed by the inventor(s) and the surcharge of \$130.00 as set forth in 37 C.F.R. § 1.16(e)
- Petition for a \_\_\_\_\_ Extension of Time
- Revocation & New Power of Attorney
- Preliminary Amendment
- Statement of Sameness


Serial No.: 09/954,737  
Filed: September 17, 2001

Paper copy of the Substitute Sequence Listing  
 Diskette copy of the Substitute Sequence Listing  
 Request for Use of an Identical Computer Readable Form in Another Application Under 37 CFR § 1.821(e)  
 Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures (copy of Notice to be returned with response)  
 Form PTO-1533 (copy of Notice to be returned with response)  
 Other: \_\_\_\_\_  
 Charge \$ \_\_\_\_\_ to Deposit Account No. 07-1048.

The Director is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16, 1.17, and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 07-1048 (Docket No. GC634-2). A duplicate of this paper is enclosed.

Respectfully submitted,

Date: 24 May 2005

  
Kamrin T. MacKnight  
Registration No. 38,230

Genencor International, Inc.  
925 Page Mill Road  
Palo Alto, CA 94304-1013  
Tel.: 650-846-7500, Ext. 5838  
Fax: 650-845-6504



## UNITED STATES PATENT AND TRADEMARK OFFICE

MAY 26 2005  
JCB  
PATENT & TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO. 09/954,737 FILING DATE 09/17/2001

5100 7590 05/02/2005

GENENCOR INTERNATIONAL, INC.  
ATTENTION: LEGAL DEPARTMENT  
925 PAGE MILL ROAD  
PALO ALTO, CA 94304

RECEIVED

FIRST NAMED INVENTOR	
Sierd Bron - 5 2005	
GCOR Patent Dept.	

ATTORNEY DOCKET NO.	CONFIRMATION NO.
GC634-2	7663
EXAMINER	
LEFFERS JR, GERALD G	
ART UNIT	PAPER NUMBER
1636	

DATE MAILED: 05/02/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

File: 634-2  
Atty: KM  
Due Date: 02-05  
Final Date: 02-05  
Type: MP 11-2-05  
STQ

**UNITED STATES PATENT AND TRADEMARK OFFICE**MAY 26 2005  
JCS

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, DC 20231  
www.uspto.gov

APPLICATION NO. / CONTROL NO.	RECEIVING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
----------------------------------	----------------	---	---------------------

**EXAMINER**

Gerald G. Leffers Jr.

ART UNIT	PAPER
----------	-------

1636 20050425

**DATE MAILED:**

**Please find below and/or attached an Office communication concerning this application or proceeding.**

**Commissioner of Patents**

The communication filed 6/9/2004 is not fully responsive to the Office communication mailed 5/24/2004 for the reason(s) set forth on the attached Notice To Comply With The Sequence Rules or CFR Diskette Problem Report. Applicant must comply with the requirements of the sequences rules (37 CFR 1.821 – 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

Since the reply appears to a bona fide attempt to comply with the requirements of the sequence rules (37 CFR 1.821 – 1.825), applicant is given a **TIME PERIOD** of **ONE (1) MONTH** from the mailing date of this communication within which to correct the deficiency so as to comply with the sequence rules (37 CFR 1.821 – 1.825) in order to avoid abandonment of the application under 37 CFR 1.821 (g). EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).


Any inquiry concerning this communication or earlier communications from the examiner should be directed to Gerald G Leffers Jr., PhD whose telephone number is (571) 272-0772. The examiner can normally be reached on 9:30am-6:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Remy Yucel can be reached on (571) 272-0781. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

**Gerald G. Leffers Jr., PhD.**  
**Primary Examiner, Art Unit 1636**

*Gerald G. Leffers Jr.*  
**GERRY LEFFERS**  
**PRIMARY EXAMINER**

**Notice to Comply**

Application No.

109/954,737

Examiner

Gerald G. Leffers Jr.

Applicant(s)

BRON ET AL.

Art Unit

1636

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- 7. Other: The submission of 6/4/2004 still does not provide sequence identifiers for sequences in Figures 1 & 7 (e.g. amino acid motifs), or for Tables 1 & 4. If these sequences are already present in the sequence listing, then all applicant needs to do is amend the specification to include the appropriate sequence identifiers. If any of these sequences are not already present in the sequence listings submitted on 6/4/2004, then applicants must provide the substitute listings and attorney's statements as indicated below.

**Applicant Must Provide:**

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY**



CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the US Postal Service with sufficient postage as First Class Mail in an envelope addressed to Mail Stop Missing Parts, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Date: May 24, 2005

By: Mari Kleineidam  
Mari Kleineidam

**PATENT**  
Attorney Docket No. GC634-2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of	)	Group Art Unit: 1636
BRON <i>et al.</i>	)	Examiner: LEFFERS, Jr., Gerald G.
Serial No.: 09/954,737	)	
Filed: September 17, 2001	)	
For: TWIN-ARGININE TRANSLOCATION IN BACILLUS	)	
	)	

STATEMENT OF SAMENESS

Mail Stop Missing Parts  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(d), the computer readable copy of the sequence listing, and the paper copy submitted herewith in the above application are believed to be the same. The present submission contains no new matter relative to the application as originally filed.

Respectfully submitted,

Dated: 24 May 2005

Kamrin T. MacKnight  
Reg. No. 38,230

Genencor International, Inc.  
925 Page Mill Road  
Palo Alto, CA 94304-1013  
Tel. (650) 846-7500, Ext. 5838  
Fax: (650) 845-6504